<?xml version="1.0" encoding="UTF-8"?>
<p>Pischke et al. (2012) stated that the HEV prevalence in 274 heart transplant recipients was 11.3% [
 <xref rid="B120-medicina-56-00206" ref-type="bibr">120</xref>]. Ribavirin and not interferon-Î± is the best therapeutic option as the latter may induce rejections. Ribavirin is effective in clearing HEV infection [
 <xref rid="B121-medicina-56-00206" ref-type="bibr">121</xref>,
 <xref rid="B122-medicina-56-00206" ref-type="bibr">122</xref>], although more dosage studies are warranted; lower doses make the treatment ineffective whereas higher doses may cause anemia.
</p>
